ArticleIn silico pharmacology2025

Development of potent inhibitors against KRAS, its mutant G12R, allosteric and Switch-I/Switch-II site.

Vikas Yadav et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.